A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica

NCT02477917 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinoconjunctivitis

Interventions

BIOLOGICAL: Allergovac depot with Parietaria judaica pollen extract

Sponsor

Roxall Medicina España S.A